Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group assumed coverage on shares of Amicus Therapeutics in a report on Wednesday, April 13th. They issued a "neutral" rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $15.25.
Amicus Therapeutics Stock Performance
Shares of NASDAQ:FOLD opened at $12.18 on Friday. The firm's 50 day moving average price is $9.95 and its 200-day moving average price is $9.01. Amicus Therapeutics has a 52-week low of $5.91 and a 52-week high of $12.69. The company has a current ratio of 4.00, a quick ratio of 3.81 and a debt-to-equity ratio of 1.63.
Amicus Therapeutics (NASDAQ:FOLD - Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. Amicus Therapeutics had a negative net margin of 87.50% and a negative return on equity of 91.37%. During the same period in the prior year, the firm earned ($0.19) EPS. On average, research analysts forecast that Amicus Therapeutics will post -0.88 earnings per share for the current year.
Insider Activity at Amicus Therapeutics
In related news, CEO John F. Crowley sold 11,346 shares of the stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $8.00, for a total transaction of $90,768.00. Following the transaction, the chief executive officer now owns 932,807 shares in the company, valued at $7,462,456. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO John F. Crowley sold 11,346 shares of the stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $8.00, for a total transaction of $90,768.00. Following the transaction, the chief executive officer now owns 932,807 shares in the company, valued at $7,462,456. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ellen Rosenberg sold 11,122 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $10.00, for a total transaction of $111,220.00. Following the transaction, the insider now owns 291,830 shares in the company, valued at approximately $2,918,300. The disclosure for this sale can be found here. Insiders have sold a total of 130,779 shares of company stock worth $1,237,966 over the last quarter. Company insiders own 2.50% of the company's stock.